Skip to main content
Erschienen in: Annals of Hematology 7/2014

01.07.2014 | Original Article

Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma

verfasst von: Aiko Kato, Yukihiro Imai, Kazunari Aoki, Sumie Tabata, Akiko Matsushita, Hisako Hashimoto, Takayuki Takahashi, Takayuki Ishikawa

Erschienen in: Annals of Hematology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Peripheral T cell lymphomas (PTCL) account for 10–15 % of non-Hodgkin’s lymphomas and are associated with poor prognosis. Although many prognostic factors for PTCL have been proposed, the heterogeneity of PTCL seems to be an obstacle in the establishment of clinically useful prognostic system, such as the International Prognostic Index (IPI) in diffuse large B cell lymphoma. PTCL with nodal manifestation include the HTLV-I-negative histologic subtypes of PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL). As PTCL-NOS encompasses a group of similar tumors and mostly shares their clinical pictures, we retrospectively analyzed clinical data from 77 patients diagnosed with ALCL, AITL, and PTCL-NOS at Kobe City Medical Center General Hospital from May 1994 to February 2012 to identify the prognostic factor for nodal PTCL. The median age of patients was 64 years, ranging from 23 to 83 years. With a median follow-up of 50 months, 5-year overall survival (OS) was 43 %. Multivariate analysis identified high-risk IPI (hazard ratio (HR), 4.04; P = 0.015), absolute monocyte count > 0.8 × 109/L (HR, 3.44; P = 0.001), and serum concentration of IgA > 410 mg/dL (HR, 2.31; P = 0.013) as poor prognostic factors for OS. Thus, we have identified novel prognostic factors of monocyte count and serum IgA level for nodal PTCL. Although conventional prognostic models mainly reflect both tumor characteristics and host factors, the present model indicates the importance of host immune response as the unfavorable prognosis.
Literatur
1.
Zurück zum Zitat Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130PubMedCrossRef Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130PubMedCrossRef
2.
Zurück zum Zitat The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994CrossRef The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994CrossRef
3.
Zurück zum Zitat Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 92:76–82PubMed Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J et al (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 92:76–82PubMed
4.
Zurück zum Zitat Sibon D, Fournier M, Briere J, Lamant L, Haioun C et al (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 30:3939–3946PubMedCrossRef Sibon D, Fournier M, Briere J, Lamant L, Haioun C et al (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte trials. J Clin Oncol 30:3939–3946PubMedCrossRef
5.
Zurück zum Zitat Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–2479PubMedCrossRef Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D et al (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103:2474–2479PubMedCrossRef
6.
Zurück zum Zitat Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S et al (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24:2472–2479PubMedCrossRef Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S et al (2006) Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol 24:2472–2479PubMedCrossRef
7.
Zurück zum Zitat Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N et al (2011) Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 22:397–404PubMedCrossRef Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N et al (2011) Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 22:397–404PubMedCrossRef
8.
Zurück zum Zitat Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E et al (2013) ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 24:857–877PubMedCrossRef Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E et al (2013) ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 24:857–877PubMedCrossRef
9.
Zurück zum Zitat Ishikawa T (2003) Current status of therapeutic approaches to adult T-cell leukemia. Int J Hematol 78:304–311PubMedCrossRef Ishikawa T (2003) Current status of therapeutic approaches to adult T-cell leukemia. Int J Hematol 78:304–311PubMedCrossRef
10.
Zurück zum Zitat de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL et al (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952–4963PubMedCrossRef de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL et al (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952–4963PubMedCrossRef
11.
Zurück zum Zitat Zettl A, Rudiger T, Konrad MA, Chott A, Simonitsch-Klupp I et al (2004) Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 164:1837–1848PubMedCentralPubMedCrossRef Zettl A, Rudiger T, Konrad MA, Chott A, Simonitsch-Klupp I et al (2004) Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 164:1837–1848PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Lenz G, Wright G, Dave SS, Xiao W, Powell J et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313–2323PubMedCrossRef Lenz G, Wright G, Dave SS, Xiao W, Powell J et al (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313–2323PubMedCrossRef
13.
Zurück zum Zitat Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T et al (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115:1026–1036PubMedCentralPubMedCrossRef Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T et al (2010) Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115:1026–1036PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN et al (2011) The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 25:1502–1509PubMedCrossRef Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN et al (2011) The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 25:1502–1509PubMedCrossRef
15.
Zurück zum Zitat Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN et al (2012) The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 53:575–580PubMedCrossRef Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN et al (2012) The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 53:575–580PubMedCrossRef
16.
Zurück zum Zitat Bari A, Tadmor T, Sacchi S, Marcheselli L, Liardo EV et al (2013) Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leuk Res 37:619–623PubMedCrossRef Bari A, Tadmor T, Sacchi S, Marcheselli L, Liardo EV et al (2013) Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leuk Res 37:619–623PubMedCrossRef
17.
Zurück zum Zitat Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T et al (2012) Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 119:2837–2843PubMedCrossRef Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T et al (2012) Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 119:2837–2843PubMedCrossRef
18.
Zurück zum Zitat Yu H, Shahsafaei A, Dorfman DM (2009) Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma. Am J Clin Pathol 131:33–41PubMedCrossRef Yu H, Shahsafaei A, Dorfman DM (2009) Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma. Am J Clin Pathol 131:33–41PubMedCrossRef
19.
Zurück zum Zitat Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H et al (2002) Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99:627–633PubMedCrossRef Attygalle A, Al-Jehani R, Diss TC, Munson P, Liu H et al (2002) Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99:627–633PubMedCrossRef
20.
Zurück zum Zitat Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A et al (2006) Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30:490–494PubMedCrossRef Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A et al (2006) Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30:490–494PubMedCrossRef
21.
Zurück zum Zitat Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood 83:1165–1173PubMed Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease? Blood 83:1165–1173PubMed
22.
Zurück zum Zitat Mourad N, Mounier N, Briere J, Raffoux E, Delmer A et al (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 111:4463–4470PubMedCentralPubMedCrossRef Mourad N, Mounier N, Briere J, Raffoux E, Delmer A et al (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 111:4463–4470PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Matsumoto Y, Horiike S, Ohshiro M, Yamamoto M, Sasaki N et al (2010) Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis. Am J Clin Pathol 133:281–290PubMedCrossRef Matsumoto Y, Horiike S, Ohshiro M, Yamamoto M, Sasaki N et al (2010) Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis. Am J Clin Pathol 133:281–290PubMedCrossRef
24.
Zurück zum Zitat Steidl C, Lee T, Shah SP, Farinha P, Han G et al (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362:875–885PubMedCentralPubMedCrossRef Steidl C, Lee T, Shah SP, Farinha P, Han G et al (2010) Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N Engl J Med 362:875–885PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Wilcox RA, Wada DA, Ziesmer SC, Elsawa SF, Comfere NI et al (2009) Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114:2936–2944PubMedCentralPubMedCrossRef Wilcox RA, Wada DA, Ziesmer SC, Elsawa SF, Comfere NI et al (2009) Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114:2936–2944PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI et al (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114:2149–2158PubMedCentralPubMedCrossRef Wilcox RA, Feldman AL, Wada DA, Yang ZZ, Comfere NI et al (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 114:2149–2158PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514PubMedCrossRef Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514PubMedCrossRef
28.
Zurück zum Zitat Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE (2012) Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica 97:262–269PubMedCentralPubMedCrossRef Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE (2012) Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica 97:262–269PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K et al (2007) Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res 31:751–757PubMedCrossRef Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K et al (2007) Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res 31:751–757PubMedCrossRef
Metadaten
Titel
Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma
verfasst von
Aiko Kato
Yukihiro Imai
Kazunari Aoki
Sumie Tabata
Akiko Matsushita
Hisako Hashimoto
Takayuki Takahashi
Takayuki Ishikawa
Publikationsdatum
01.07.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 7/2014
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2025-0

Weitere Artikel der Ausgabe 7/2014

Annals of Hematology 7/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.